Together, the data suggest that all three MDAMB436 OR clones have acquired similar CC50 values to those seen in BRCA WT breast cancer cell lines (62) by reestablishing BRCA1 expression and HDR functionality and with that eliminating the synthetic lethal effect that its absence has with PARP inhibition. Here, PARP1 is linked to breast carcinoma.